An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs AAV-hFIX (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2016 Planned End Date changed from 1 Jul 2031 to 1 Dec 2032.
- 09 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.